ArticleJCO oncology advances2025

Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for

Erica S Tsang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.